Serum Matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer

Kouichirou Tahara, Koshi Mimori, Hisae Iinuma, Masaaki Iwatsuki, Takehiko Yokobori, Hideshi Ishii, Hideaki Anai, Seigo Kitano, Masaki Mori

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Matrix metalloproteinases (MMPs) are involved in the degradation of extracellular matrix components and are associated with invasion and metastasis. MMP proteins could be serum tumor markers or molecular targets in the treatment of malignancy. The purpose of the current study was to identify a prognostic serum marker in cases of colorectal cancer (CRC) prior to surgical intervention. Materials and Methods: Laser microdissection and microarray analysis were used to characterize gene expression in 73 cases of CRC. We then focused on expression of MMP-1. We examined serum MMP-1 activity before resection in another subset of 75 cases of CRC to validate the clinical significance of MMP-1 as a prognostic marker in CRC after surgically curative operation. Results: Disease-free survival was 51% in the MMP-1 high expression group and 81% in the low-expression group (P < .05). Survival was 52% in the MMP-1 high expression group and 90% in the low group (P < .05). In multivariate analysis for disease-free survival, MMP-1 and lymph node metastasis were significant independent prognostic indicators. In multivariate analysis of overall survival, serum MMP-1 level was the only significant independent indicator among factors. Conclusions: Within the MMP family of proteins, MMP-1 is not a cancer-specific protease. However, MMP-1 activity does predict the future course of progression of malignant cells. Thus, MMP-1, which is activated at the primary lesion and is found in serum, assists in the clinical diagnosis of CRC. It is also an important molecule for understanding the underlying mechanism of invasion and metastasis of CRC.

Original languageEnglish
Pages (from-to)3362-3369
Number of pages8
JournalAnnals of Surgical Oncology
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 1 2010

Fingerprint

Matrix Metalloproteinase 1
Colorectal Neoplasms
Serum
Matrix Metalloproteinases
Neoplasm Metastasis
Disease-Free Survival
Multivariate Analysis
Biomarkers
Microdissection
Microarray Analysis
Tumor Biomarkers
Extracellular Matrix
Neoplasms
Proteins
Lasers
Peptide Hydrolases
Lymph Nodes
Gene Expression

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Serum Matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer. / Tahara, Kouichirou; Mimori, Koshi; Iinuma, Hisae; Iwatsuki, Masaaki; Yokobori, Takehiko; Ishii, Hideshi; Anai, Hideaki; Kitano, Seigo; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 17, No. 12, 01.12.2010, p. 3362-3369.

Research output: Contribution to journalArticle

Tahara, K, Mimori, K, Iinuma, H, Iwatsuki, M, Yokobori, T, Ishii, H, Anai, H, Kitano, S & Mori, M 2010, 'Serum Matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer', Annals of Surgical Oncology, vol. 17, no. 12, pp. 3362-3369. https://doi.org/10.1245/s10434-010-1149-2
Tahara, Kouichirou ; Mimori, Koshi ; Iinuma, Hisae ; Iwatsuki, Masaaki ; Yokobori, Takehiko ; Ishii, Hideshi ; Anai, Hideaki ; Kitano, Seigo ; Mori, Masaki. / Serum Matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 12. pp. 3362-3369.
@article{f3892a5b834048119f274a615cf8b393,
title = "Serum Matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer",
abstract = "Background: Matrix metalloproteinases (MMPs) are involved in the degradation of extracellular matrix components and are associated with invasion and metastasis. MMP proteins could be serum tumor markers or molecular targets in the treatment of malignancy. The purpose of the current study was to identify a prognostic serum marker in cases of colorectal cancer (CRC) prior to surgical intervention. Materials and Methods: Laser microdissection and microarray analysis were used to characterize gene expression in 73 cases of CRC. We then focused on expression of MMP-1. We examined serum MMP-1 activity before resection in another subset of 75 cases of CRC to validate the clinical significance of MMP-1 as a prognostic marker in CRC after surgically curative operation. Results: Disease-free survival was 51{\%} in the MMP-1 high expression group and 81{\%} in the low-expression group (P < .05). Survival was 52{\%} in the MMP-1 high expression group and 90{\%} in the low group (P < .05). In multivariate analysis for disease-free survival, MMP-1 and lymph node metastasis were significant independent prognostic indicators. In multivariate analysis of overall survival, serum MMP-1 level was the only significant independent indicator among factors. Conclusions: Within the MMP family of proteins, MMP-1 is not a cancer-specific protease. However, MMP-1 activity does predict the future course of progression of malignant cells. Thus, MMP-1, which is activated at the primary lesion and is found in serum, assists in the clinical diagnosis of CRC. It is also an important molecule for understanding the underlying mechanism of invasion and metastasis of CRC.",
author = "Kouichirou Tahara and Koshi Mimori and Hisae Iinuma and Masaaki Iwatsuki and Takehiko Yokobori and Hideshi Ishii and Hideaki Anai and Seigo Kitano and Masaki Mori",
year = "2010",
month = "12",
day = "1",
doi = "10.1245/s10434-010-1149-2",
language = "English",
volume = "17",
pages = "3362--3369",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Serum Matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer

AU - Tahara, Kouichirou

AU - Mimori, Koshi

AU - Iinuma, Hisae

AU - Iwatsuki, Masaaki

AU - Yokobori, Takehiko

AU - Ishii, Hideshi

AU - Anai, Hideaki

AU - Kitano, Seigo

AU - Mori, Masaki

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: Matrix metalloproteinases (MMPs) are involved in the degradation of extracellular matrix components and are associated with invasion and metastasis. MMP proteins could be serum tumor markers or molecular targets in the treatment of malignancy. The purpose of the current study was to identify a prognostic serum marker in cases of colorectal cancer (CRC) prior to surgical intervention. Materials and Methods: Laser microdissection and microarray analysis were used to characterize gene expression in 73 cases of CRC. We then focused on expression of MMP-1. We examined serum MMP-1 activity before resection in another subset of 75 cases of CRC to validate the clinical significance of MMP-1 as a prognostic marker in CRC after surgically curative operation. Results: Disease-free survival was 51% in the MMP-1 high expression group and 81% in the low-expression group (P < .05). Survival was 52% in the MMP-1 high expression group and 90% in the low group (P < .05). In multivariate analysis for disease-free survival, MMP-1 and lymph node metastasis were significant independent prognostic indicators. In multivariate analysis of overall survival, serum MMP-1 level was the only significant independent indicator among factors. Conclusions: Within the MMP family of proteins, MMP-1 is not a cancer-specific protease. However, MMP-1 activity does predict the future course of progression of malignant cells. Thus, MMP-1, which is activated at the primary lesion and is found in serum, assists in the clinical diagnosis of CRC. It is also an important molecule for understanding the underlying mechanism of invasion and metastasis of CRC.

AB - Background: Matrix metalloproteinases (MMPs) are involved in the degradation of extracellular matrix components and are associated with invasion and metastasis. MMP proteins could be serum tumor markers or molecular targets in the treatment of malignancy. The purpose of the current study was to identify a prognostic serum marker in cases of colorectal cancer (CRC) prior to surgical intervention. Materials and Methods: Laser microdissection and microarray analysis were used to characterize gene expression in 73 cases of CRC. We then focused on expression of MMP-1. We examined serum MMP-1 activity before resection in another subset of 75 cases of CRC to validate the clinical significance of MMP-1 as a prognostic marker in CRC after surgically curative operation. Results: Disease-free survival was 51% in the MMP-1 high expression group and 81% in the low-expression group (P < .05). Survival was 52% in the MMP-1 high expression group and 90% in the low group (P < .05). In multivariate analysis for disease-free survival, MMP-1 and lymph node metastasis were significant independent prognostic indicators. In multivariate analysis of overall survival, serum MMP-1 level was the only significant independent indicator among factors. Conclusions: Within the MMP family of proteins, MMP-1 is not a cancer-specific protease. However, MMP-1 activity does predict the future course of progression of malignant cells. Thus, MMP-1, which is activated at the primary lesion and is found in serum, assists in the clinical diagnosis of CRC. It is also an important molecule for understanding the underlying mechanism of invasion and metastasis of CRC.

UR - http://www.scopus.com/inward/record.url?scp=78650972254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650972254&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1149-2

DO - 10.1245/s10434-010-1149-2

M3 - Article

C2 - 20617463

AN - SCOPUS:78650972254

VL - 17

SP - 3362

EP - 3369

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -